
Bong-sook Baek
Examiner (ID: 19234, Phone: (571)270-5863 , Office: P/1621 )
| Most Active Art Unit | 1611 |
| Art Unit(s) | 1629, 1614, 1611, 1621, 4161 |
| Total Applications | 1191 |
| Issued Applications | 499 |
| Pending Applications | 85 |
| Abandoned Applications | 621 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17640504
[patent_doc_number] => 20220168242
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => PHARMACEUTICALLY ACCEPTABLE SALTS OF MESDOPETAM AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/454110
[patent_app_country] => US
[patent_app_date] => 2021-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19030
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17454110
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/454110 | PHARMACEUTICALLY ACCEPTABLE SALTS OF MESDOPETAM AND USES THEREOF | Nov 8, 2021 | Abandoned |
Array
(
[id] => 17595223
[patent_doc_number] => 20220144796
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => 2-[Thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use therof as medicament
[patent_app_type] => utility
[patent_app_number] => 17/518608
[patent_app_country] => US
[patent_app_date] => 2021-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12894
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17518608
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/518608 | 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament | Nov 3, 2021 | Issued |
Array
(
[id] => 17398038
[patent_doc_number] => 20220040128
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM
[patent_app_type] => utility
[patent_app_number] => 17/502562
[patent_app_country] => US
[patent_app_date] => 2021-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26976
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17502562
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/502562 | METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM | Oct 14, 2021 | Abandoned |
Array
(
[id] => 19613341
[patent_doc_number] => 20240399021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => ANTIMICROBIAL COMPOSITION AND METHOD FOR MAKING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/700760
[patent_app_country] => US
[patent_app_date] => 2021-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10300
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18700760
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/700760 | ANTIMICROBIAL COMPOSITION AND METHOD FOR MAKING THE SAME | Oct 12, 2021 | Pending |
Array
(
[id] => 17759906
[patent_doc_number] => 20220233518
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/498507
[patent_app_country] => US
[patent_app_date] => 2021-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63816
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498507
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/498507 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Oct 10, 2021 | Abandoned |
Array
(
[id] => 20607033
[patent_doc_number] => 12582612
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-24
[patent_title] => Pharmaceutical composition of Siglec-binding agents
[patent_app_type] => utility
[patent_app_number] => 17/494555
[patent_app_country] => US
[patent_app_date] => 2021-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 36
[patent_no_of_words] => 14112
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494555
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/494555 | Pharmaceutical composition of Siglec-binding agents | Oct 4, 2021 | Issued |
Array
(
[id] => 17472421
[patent_doc_number] => 20220079925
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-17
[patent_title] => COMPOSITIONS COMPRISING TACROLIMUS FOR THE TREATMENT OF INTRAOCULAR INFLAMMATORY EYE DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/486634
[patent_app_country] => US
[patent_app_date] => 2021-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11455
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486634
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/486634 | COMPOSITIONS COMPRISING TACROLIMUS FOR THE TREATMENT OF INTRAOCULAR INFLAMMATORY EYE DISEASES | Sep 26, 2021 | Pending |
Array
(
[id] => 18692496
[patent_doc_number] => 20230322771
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => HETEROCYCLIC GLP-1 AGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/044196
[patent_app_country] => US
[patent_app_date] => 2021-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26280
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -203
[patent_words_short_claim] => 1066
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044196
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/044196 | HETEROCYCLIC GLP-1 AGONISTS | Sep 5, 2021 | Pending |
Array
(
[id] => 18221183
[patent_doc_number] => 20230060177
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => METHOD FOR TREATING ATHLETES SUBJECT TO PATHOLOGICAL CARDIAC HYPERTROPHY BY ADMINISTERING NIGELLA SATIVA
[patent_app_type] => utility
[patent_app_number] => 17/406895
[patent_app_country] => US
[patent_app_date] => 2021-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12603
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17406895
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/406895 | METHOD FOR TREATING ATHLETES SUBJECT TO PATHOLOGICAL CARDIAC HYPERTROPHY BY ADMINISTERING NIGELLA SATIVA | Aug 18, 2021 | Abandoned |
Array
(
[id] => 17858498
[patent_doc_number] => 11439636
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-09-13
[patent_title] => Bupropion as a modulator of drug activity
[patent_app_type] => utility
[patent_app_number] => 17/405429
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 25
[patent_no_of_words] => 64127
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405429
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/405429 | Bupropion as a modulator of drug activity | Aug 17, 2021 | Issued |
Array
(
[id] => 17519227
[patent_doc_number] => 20220105075
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => CHEMICAL COMPOSITIONS AND METHODS FOR ENHANCING TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/402807
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8799
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402807
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/402807 | CHEMICAL COMPOSITIONS AND METHODS FOR ENHANCING TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS | Aug 15, 2021 | Abandoned |
Array
(
[id] => 17355312
[patent_doc_number] => 20220016108
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/401371
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25435
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17401371
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/401371 | Quinolines that modulate SERCA and their use for treating disease | Aug 12, 2021 | Issued |
Array
(
[id] => 17413994
[patent_doc_number] => 20220048898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/401642
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42612
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17401642
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/401642 | Quinolines that modulate SERCA and their use for treating disease | Aug 12, 2021 | Issued |
Array
(
[id] => 17412667
[patent_doc_number] => 20220047571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV2 INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/402419
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61659
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402419
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/402419 | Compositions for and methods of inhibiting SARS-CoV2 infection | Aug 12, 2021 | Issued |
Array
(
[id] => 17256618
[patent_doc_number] => 20210369603
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => DOSAGE FORM FOR VAPORIZATION AND SMOKING
[patent_app_type] => utility
[patent_app_number] => 17/400359
[patent_app_country] => US
[patent_app_date] => 2021-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10458
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400359
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/400359 | Dosage form for vaporization and smoking | Aug 11, 2021 | Issued |
Array
(
[id] => 17272822
[patent_doc_number] => 20210379020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => COMPOUNDS FOR THE TREATMENT OF MALARIA
[patent_app_type] => utility
[patent_app_number] => 17/399589
[patent_app_country] => US
[patent_app_date] => 2021-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15869
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17399589
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/399589 | COMPOUNDS FOR THE TREATMENT OF MALARIA | Aug 10, 2021 | Abandoned |
Array
(
[id] => 17398137
[patent_doc_number] => 20220040227
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME
[patent_app_type] => utility
[patent_app_number] => 17/398156
[patent_app_country] => US
[patent_app_date] => 2021-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14972
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17398156
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/398156 | METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME | Aug 9, 2021 | Abandoned |
Array
(
[id] => 17821478
[patent_doc_number] => 11426401
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-30
[patent_title] => Bupropion as a modulator of drug activity
[patent_app_type] => utility
[patent_app_number] => 17/395222
[patent_app_country] => US
[patent_app_date] => 2021-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 25
[patent_no_of_words] => 63949
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17395222
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/395222 | Bupropion as a modulator of drug activity | Aug 4, 2021 | Issued |
Array
(
[id] => 17398064
[patent_doc_number] => 20220040154
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA
[patent_app_type] => utility
[patent_app_number] => 17/395059
[patent_app_country] => US
[patent_app_date] => 2021-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39719
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -68
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17395059
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/395059 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA | Aug 4, 2021 | Pending |
Array
(
[id] => 18227953
[patent_doc_number] => 20230066947
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => Method for the augmentation of substance abuse therapies using cannabinoid formulations
[patent_app_type] => utility
[patent_app_number] => 17/394398
[patent_app_country] => US
[patent_app_date] => 2021-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4966
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394398
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/394398 | Method for the augmentation of substance abuse therapies using cannabinoid formulations | Aug 3, 2021 | Abandoned |